Earnings

Earnings Articles

Kohl’s posted better-than-expected fiscal third-quarter earnings and offered guidance before the markets opened on Thursday.
Macy's reported mixed fiscal third-quarter financial results and offered guidance before the markets opened on Thursday.
Mylan N.V. (NASDAQ: MYL) released third-quarter earnings after markets closed on Wednesday. The company posted $1.38 in earnings per share (EPS) and $3.23 billion in revenue. The consensus estimates...
Like many other alternative energy stocks, SunPower Corp. (NASDAQ: SPWR) took a beating today as investors fled alternative energy stocks following Tuesday’s election. Incentives and subsidies are...
Novavax, Inc. (NASDAQ: NVAX) reported third-quarter financial results after markets closed on Wednesday. The company said that it had a net loss of $0.24 per share and $3.2 million in revenue, versus...
Sucampo Pharmaceuticals reported better-than-expected third-quarter financial results before the markets opened on Wednesday.
EpiPen maker Mylan is scheduled to report its third-quarter financial results after the markets close on Wednesday.
Ionis Pharmaceuticals reported disappointing third-quarter financial results before the markets opened on Wednesday.
BioScrip, Inc. (NASDAQ: BIOS) reported third-quarter financial results before the markets opened on Tuesday. The company said that it had a net loss of $0.09 per share and $224.5 million in revenues....
Novavax is scheduled to report its third-quarter financial results before the markets open on Wednesday.
Shares of Hertz Global were cut in half on Tuesday after the company missed earnings in its most recent report.
After Acadia Pharmaceuticals released its third-quarter earnings report after the markets closed on Monday, shares rose sharply Tuesday morning.
After Depomed reported disappointing third-quarter financial results after the markets closed on Monday, shares tumbled early Tuesday.
Vivint Solar is scheduled to report its third-quarter financial results after the markets close on Tuesday.
Over the past month, Valeant Pharmaceuticals sank to just above its 52-week low, but it appears that it has now been pushed over the edge with this most recent earnings report.